Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

65.50
-0.9800-1.47%
Volume:428.01K
Turnover:28.08M
Market Cap:5.47B
PE:-107.38
High:66.54
Open:66.51
Low:65.06
Close:66.48
52wk High:90.87
52wk Low:57.74
Shares:83.46M
Float Shares:73.65M
Volume Ratio:0.58
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6100
EPS(LYR):7.78
ROE:-7740.12%
ROA:2.46%
PB:-33.06
PE(LYR):8.42

Loading ...

PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy

TIPRANKS
·
Aug 13

PTC Therapeutics, Inc. : Wells Fargo Raises Target Price to $109 from $106

THOMSON REUTERS
·
Aug 13

Sangamo Selects Winning Bids in Chapter 11 Asset Auction for USD 163.55 Million Cash at Close

Reuters
·
Aug 13

PTC Therapeutics to Buy Sangamo’s ST-920 Fabry Gene Therapy Program for $111 Million Upfront

Reuters
·
Aug 13

PTC Therapeutics, - to Buy St-920 Gene Therapy for Fabry Disease from Sangamo

THOMSON REUTERS
·
Aug 13

PTC Therapeutics, - Rolling Bla Submission for St-920 Expected to Complete in Q4 2026

THOMSON REUTERS
·
Aug 13

PTC Therapeutics, - Deal Terms Include $111 Mln Upfront and up to $100 Mln in Milestone Payments

THOMSON REUTERS
·
Aug 13

PTC to Expand Rare Disease Portfolio with Acquisition of Bla-Stage St-920 Fabry Disease Program

THOMSON REUTERS
·
Aug 13

Press Release: PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

Dow Jones
·
Aug 13

Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Aug 03

PTC Therapeutics is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Aug 01

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Regeneron (REGN) and PTC Therapeutics (PTCT)

TIPRANKS
·
Jul 31

Werewolf Therapeutics Posts Q2 Profit on Jazz Asset Sale

Reuters
·
Jul 31

PTC Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

PTC Therapeutics Director Hege Elisabeth Sollie-Zetlmayer Files Initial Beneficial Ownership Statement

Reuters
·
Jul 31

PTC Therapeutics Raises Outlook on Strong Q2 Results

TIPRANKS
·
Jul 31

PTC Therapeutics Posts Corporate Presentation Highlighting Sephience PKU Launch Momentum

Reuters
·
Jul 31

GUIDANCE: (PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B

MT Newswires Live
·
Jul 31

Earnings Flash (PTCT) PTC Therapeutics Posts Q2 EPS $0.92, vs. FactSet Est of $0.24

MT Newswires Live
·
Jul 31

PTC Therapeutics Q2 FY26 Net Income Swings to $83.5 Million; Revenue More than Doubles to $361 Million

Reuters
·
Jul 31